Save the federal drug pricing program

To the Editor;

Maine’s health care system is facing a crisis, with hospitals and community health centers struggling to stay afloat. The recent closure of Northern Light Inland Hospital in Waterville is just one example of the ramifications of the financial strain on our state’s hospitals. Now, more than ever, we must protect vital programs like the federal 340B drug pricing program, which provides crucial support to health care providers serving low-income and underserved populations.

The 340B program enables hospitals and community health centers to purchase discounted drugs and reinvest the savings into essential health services. Despite these benefits, pharmaceutical companies are actively working to undermine the program by restricting access to discounted drugs, costing Maine providers millions annually. The impact is especially severe in rural areas, where access to care is already limited.

Maine lawmakers must take action to safeguard 340B by passing LD 1018, which would close loopholes that allow drug manufacturers to deny access to these critical discounts. This legislation would ensure continued support for essential services such as cancer treatment, dental care, and care for uninsured patients.

Protecting 340B does not cost Maine taxpayers a dime, but losing it would mean fewer health care services, especially in the communities that need them most. In this time of federal and state budgetary pressures that threaten health care access for our most vulnerable populations, lawmakers must stand up for Maine’s non-profit hospitals and health centers by defending 340B against the interests of the for-profit drug companies. Our health care system — and the people it serves — depend on it.

Jay Reynolds, MD

president, Northern Light A.R. Gould Hospital

Presque Isle